article thumbnail

Two common biomarkers can predict heart risk in asymptomatic childhood cancer survivors

Medical Xpress - Cardiology

Jude LIFE) have revealed that two common biomarkers of cardiac function and damage could better predict cardiomyopathy within five years than routine clinical evaluations in high-risk, asymptomatic childhood cancer survivors. Jude lifetime cohort study (St.

article thumbnail

Treatment-Specific Biomarkers, Future of Research for Lung Cancer with Jonathan Spicer, MD, PhD

HCPLive

In this Lungcast segment, Spicer spoke on several treatment-specific biomarkers for lung cancer and discussed the future of lung cancer therapy.

article thumbnail

Two common biomarkers predict heart risk in asymptomatic childhood cancer survivors

Science Daily - Heart Disease

Scientists have found that two common biomarkers could predict cardiomyopathy that is otherwise undetected by conventional screenings in childhood cancer survivors.

article thumbnail

Targeting eIF4A triggers an interferon response to synergize with chemotherapy and suppress triple-negative breast cancer

Journal of Clinical Investigation - Cardiology

Protein synthesis is frequently dysregulated in cancer and selective inhibition of mRNA translation represents an attractive cancer therapy. A similar induction of IFN-stimulated genes was observed in breast cancer patient biopsies following zotatifin treatment.

Cancer 98
article thumbnail

Soluble immune-checkpoint factors: a potential immunotherapy biomarker

Journal of Clinical Investigation - Cardiology

There is unmet need for additional biomarkers to better select patients with non–small cell lung cancer (NSCLC) that are likely to benefit from immunotherapy in order to improve patient outcomes, reduce patient toxicity, and relieve the growing burden of healthcare costs.

article thumbnail

ACE Inhibitor Not Protective Against Heart Damage from Chemotherapy

DAIC

The PROACT study reported no impact on cardiotoxicity biomarkers or secondary endpoints related to heart function among patients who took high doses of enalapril, an ACE inhibitor, along with high doses of anthracyclines. Anthracyclines are a well-established class of cancer drugs that are used to treat several types of cancer.

article thumbnail

Unhealthy visceral fat is associated with improved efficacy of immunotherapy in endometrial cancer

Journal of Clinical Investigation - Cardiology

Obesity is a known driver of endometrial cancer. In this issue of the JCI, Gómez-Banoy and colleagues investigated a cohort of patients with advanced endometrial cancer treated with immune checkpoint inhibitors targeting the interaction between programmed cell death receptor-1 (PD-1) and its ligand (PD-L1).

Cancer 63